Brazil Addiction Therapeutics Market Analysis

Brazil Addiction Therapeutics Market Executive Summary

Brazil addiction therapeutics market was valued at $253 Mn in 2022 and is estimated to reach $464 Mn in 2030, exhibiting a CAGR of 7.9% during the forecast period.

Addiction therapies are the umbrella term for a variety of approaches, interventions, and techniques used to treat and prevent addiction. Its main goal is to reduce or eliminate substance addiction, especially that which involves drugs and alcohol, in order to treat people who are suffering from dependency and co-occurring illnesses. Effective addiction therapy usually takes a customised and all-encompassing strategy, considering the unique circumstances, past drug use, co-occurring conditions, and social support of each patient. Methadone and buprenorphine are two commonly used drugs prescribed as part of continuing treatment for opioid use disorder addiction. Acamprosate, disulfiram, and naltrexone are a few more drugs that are approved for the treatment of substance use disorders; however, they might not be started until after detox is over.

Individuals who were homeless for a minimum of 12 months and who were 18 years of age or older had at least one psychiatric disorder diagnosed in them. The most common psychiatric disorders were alcohol addiction/abuse (82.0%), mood disorders (32.5%), drug addiction/abuse (31.3%), and schizophreniform psychosis (9.6%), indicating a high comorbidity index (78.3%). These results are linked to the countrywide shortcomings in the homelessness support system. Brazil has been identified by the United Nations Office on Drugs and Crime as one of the developing countries experiencing an increase in stimulant use, specifically cocaine used intranasally ("powder") or smoked (crack, and similar forms like "merla" or "oxi").

A novel vaccination called "Calixcoca," which is intended to trigger an immune response that blocks the brain's ability to absorb cocaine and crack, is being developed by researchers at the Federal University of Minas Gerais, Brazil. With this innovative vaccine, people who are addicted to substances should not relapse by reducing their desires. While in pre-clinical testing, Calixcoca has shown promising results in animal models, suggesting that, with successful human trials, it may revolutionize the treatment of cocaine addiction.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Addiction: Brazil has the highest rate of alcohol use in Latin America, with an estimated 23% of the population being heavy drinkers. Cocaine and crack cocaine are the most common illegal narcotics, and drug use is another developing concern. Drug addiction cases are on the rise due to the rising availability of narcotics. As a result, there is an increase in the addiction therapeutics market.

Awareness and Education Initiatives: The Brazilian market for addiction therapies is growing as a result of ongoing campaigns, educational programs, and initiatives by governmental and non-governmental organizations that work to lessen stigma, support early intervention, and encourage help-seeking behaviours.

Technological Advancements in Treatment: By providing more effective and varied treatment alternatives, new medications, therapies, and technological interventions, together with other advancements in addiction therapeutics and treatment methodology, technological advancements support market expansion.

Market Restraints

Regulatory Challenges: Innovative addiction therapies can face obstacles in their introduction and adoption to the market, due to strict restrictions, protracted approval processes for new medications or therapies, and barriers linked to compliance.

Stigma and Perception: People's willingness to seek treatment is hampered by enduring social stigma and unfavourable views about addiction and mental health problems, which restricts the market's potential for expansion.

High Cost of Treatment: A large percentage of the population, especially those from lower socioeconomic classes, may find private addiction treatment to be unaffordable due to their heavy expenses. It is possible that many people from lower socioeconomic backgrounds will have difficulty accessing high-quality private addiction treatment services.

Notable Recent Updates

• June 2021, Indivior plc and Aelis Farma announced a strategic partnership and option-license agreement to address the significant repercussions of cannabis use disorders (CUD), including cannabis-induced psychosis (CIP).
• May 2021, JB Chemicals & Pharmaceuticals Ltd (JBCPL) launched NOSMOK prescription-medicated nicotine lozenges on "World No Tobacco Day" as part of a 360 Tobacco Cessation initiative. These lozenges will help reduce the desire to use tobacco.

Healthcare Policies and Regulatory Landscape

Several frameworks and efforts are included in Brazil's regulatory environment for addiction therapies and healthcare policy. Although issues like congestion and financial constraints affect service quality, the Unified Health System (SUS) provides free or inexpensive healthcare services, including addiction treatment. Drug registration, production, and distribution compliance are supervised by ANVISA (National Health Surveillance Agency, Agência Nacional de Vigilância Sanitária). Strict evaluations are usually part of the licensing procedure, which guarantees the quality, safety, and efficacy of pharmaceuticals meant for the market. With treatment and preventative services, the Crack, It's Possible to Overcome Program aims to combat crack cocaine addiction. Addiction therapy guidelines are monitored by regulatory agencies, and non-governmental organizations (NGOs) augment these efforts with community-based initiatives and assistance.

Competitive Landscape

Key Players

• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Titan Pharmaceutical
• Indivior
• Novartis
• Cipla
• Mylan
• Glenmark
• Alkermes